Oxaliplatin and/or gemcitabine vs. FOLFIRINOX in first-line Advanced pancreatic adenocarcinoma: Real-world efficacy and safety data of moroccan patients

Background: While fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) offers a survival advantage in advanced pancreatic adenocarcinoma (PAC) compared to gemcitabine, gemcitabine-oxaliplatin, and gemcitabine-nab-paclitaxel, the outcome of these regimens in African countries is still i...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Hassan Abdelilah Tafenzi, Youssef Ait Takniouine, Ismail Essadi, Rhizlane Belbaraka
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Elsevier 2025-01-01
Reeks:	Cancer Treatment and Research Communications
Onderwerpen:	RWD Unresectable PAC First-line treatment
Online toegang:	http://www.sciencedirect.com/science/article/pii/S2468294225001728
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!